Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Up 168.1% in October

Altamira Therapeutics Ltd. (NASDAQ:CYTO) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 31,100 shares, a growth of 168.1% from the October 15th total of 11,600 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average trading volume of 366,500 shares, the short-interest ratio is presently 0.1 days.

Altamira Therapeutics Trading Up 3.7 %

Altamira Therapeutics stock opened at $0.43 on Friday. Altamira Therapeutics has a 12-month low of $0.40 and a 12-month high of $17.20. The firm’s fifty day moving average is $0.62 and its 200 day moving average is $1.03.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.